Findings

What do systematic reviews say?

4,929 questions · 15,174 findings · 2,372 reviews

Sort:Best matchNewestHighest certainty Download CSV

No studies found 15,174 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

QoL

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DFX film‐coated tablet vs DFX dispersible tablet

QoL

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DFP and DFO vs DFP

Sustained adherence

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DFP and DFO vs DFP

QoL

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DFP and DFO vs deferoxamine

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DFP and DFO vs deferoxamine

Sustained adherence

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DFP and DFO vs deferoxamine

QoL

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DFP and DFO vs DFP and DFX

Sustained adherence

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Medication management vs usual care

Adherence to iron chelation therapy (%, SD)

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Medication management vs usual care

SAEs

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

Sustained adherence

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Medication management vs usual care

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Medication management vs usual care

Sustained adherence

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs vitamin C

Serious adverse events · children with sickle cell anaemia and microalbuminuria

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs vitamin C

Mortality due to any cause · children with sickle cell anaemia and microalbuminuria

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs vitamin C

Quality of life · children with sickle cell anaemia and microalbuminuria

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydroxyurea vs placebo

Quality of life · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

Serious adverse events · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

All‐cause mortality · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

Quality of life · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found